Open-Angle Glaucoma Market Insights, Epidemiology and Market Forecast-2030

Open-Angle Glaucoma Market Insights, Epidemiology and Market Forecast-2030

DelveInsight’s Open-angle glaucoma (OAG) – Market Insights, Epidemiology, and Market Forecast—2030 (7MM) report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of OAG in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Open-Angle Glaucoma Market Insights, Epidemiology and Market Forecast-2030

 (Albany, US) DelveInsight launched a new report on Open-Angle Glaucoma Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report

  1. The total Glaucoma prevalent population was 9,819,080 in the 7MM in 2017.
  2. The total diagnosed prevalent population of Open-Angle Glaucoma (OAG) in the 7MM was 8,823,960 in 2017.
  3. The prevalent cases of OAG in the United States in 2017 was 2,749,378.
  4. The most prevalent age-group for OAG in the United States in 2017 was 70–79.


Key benefits of the report

1.    Open-Angle Glaucoma market report covers a descriptive overview and comprehensive insight of the Open-Angle Glaucoma epidemiology and Open-Angle Glaucoma market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2.    Open-Angle Glaucoma market report provides insights into the current and emerging therapies.

3.    Open-Angle Glaucoma market report provides a global historical and forecasted market covering drug outreach in 7 MM.

4.    Open-Angle Glaucoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Open-Angle Glaucoma market.

Request for sample pages

“Open-Angle Glaucoma Market Size was USD 3,316.71 million in the 7MM in 2017”.



The main goal of glaucoma treatment is to increase the quality of life through the reduction of intraocular pressure (IOP) to preserve visual function. In the process of IOP reduction, an ideal medication should have a schedule that is simple to follow, be least interrupting with a patient’s life, highly tolerable and affordable.


However, the medical treatment of Glaucoma has associated side effects, complications, and costs. There are several risk factors like age more than 60 years, genetic predisposition, certain eye characteristics (such as a pupillary defect, thin cornea, myopia), low educational status, smoking, African descent, and visual problems are associated with this indication and treatment pattern varies accordingly.


Management of the disease aims at lowering intraocular pressure (IOP) with the current class of drugs, like prostaglandin analogues, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors.


Prostaglandin analogues are the first treatment choice for many glaucoma patients. Before the entry of prostaglandins in the market, Beta-blockers were quite famous and popular for the management of Glaucoma. Ocular hypotensive agents other than beta-blockers, such as the alpha2 agonist brimonidine, maybe a more appropriate first-line therapy for ocular hypertension and glaucoma patients concurrently taking systemic beta-blockers.


The launch of the emerging therapies is expected to significantly impact Open-Angle Glaucoma treatment scenario in the upcoming years:-

Drugs covered

  • Bimatoprost SR
  • PDP-716
  • PRO-122
  • DE-130A
  • CKD-351
  • NCX 470
  • Bamosiran
  • ENV515
  • Nyxol
  • POLAT-001
  • Trabodenoson
  • OTX-TP


And many others

The key players in Open-Angle Glaucoma market are:

  • Allergan
  • Sun Pharma Advanced Research Company Limited (SPARC)
  • Laboratorios Sophia S.A de C.V.
  • Santen Pharmaceutical
  • Chong Kun Dang Pharmaceutical
  • Nicox Ophthalmics
  • Sylentis
  • Envisia Therapeutics
  • Ocuphire Pharma
  • Peregrine Ophthalmic
  • Inotek Pharmaceuticals
  • Ocular Therapeutix


And many others

Table of contents

1. Key Insights


2. Executive Summary of Open-Angle Glaucoma


3. Open-Angle Glaucoma Market Overview at a Glance


4. Open-Angle Glaucoma Disease Background and Overview


5. Case Reports


6. Open-Angle Glaucoma Epidemiology and Patient Population


7. United States Epidemiology


8. EU5 Epidemiology


8.1. Germany Epidemiology


8.2. France Epidemiology


8.3. Italy Epidemiology


8.4. Spain Epidemiology


8.5. United Kingdom Epidemiology


9. Japan Epidemiology


10. Open-Angle Glaucoma Treatment Algorithm, Current Treatment, and Medical Practices


11. Unmet Needs


12. Open-Angle Glaucoma Marketed Products


12.1. Marketed Products And Their Relative Therapeutic Classes


12.2. ROCKLATAN: Aerie Pharmaceuticals


12.3. Rhopressa: Aerie Pharmaceuticals


12.4. XELPROS (latanoprost ophthalmic emulsion) 0.005%: Sun Pharma Advanced Research Company Limited


12.5. EYBELIS Ophthalmic Solution 0.002% (DE-117, Omidenepag isopropyl): Santen Pharmaceutical/Ube Industries


12.6. VYZULTA: Bausch and Lomb


12.7. TAPCOM/ DE-111 (Tafluprost/timolol maleate): Santen Pharmaceutical Co., Ltd.


12.8. GLANATEC: D.Western Therapeutics Institute (DWTI)/Kowa LTD.


12.9. Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%: Alcon Research


12.10. ZIOPTAN (tafluprost): Merck Sharp & Dohme Corp.


12.11. DuoTrav PQ (travoprost/timolol): Novartis/Alcon Research


12.12. TRAVATAN Z (travoprost ophthalmic solution) 0.004%: Alcon Research, a Novartis company


12.13. LUMIGAN 0.01% (bimatoprost ophthalmic solution): Allergan


13. Open-Angle Glaucoma Emerging Therapies


13.1. Key Cross Competition


13.2. Bimatoprost SR (Sustained-Release): Allergan

13.3. PDP-716: Sun Pharma Advanced Research Company Limited (SPARC)


13.4. PRO-122: Laboratorios Sophia S.A de C.V.


13.5. Brinzolamide Ophthalmic Suspension 1%: Perrigo Company


13.6. DE-130A (latanoprost): Santen Pharmaceutical


13.7. CKD-351: Chong Kun Dang Pharmaceutical


13.8. Sepetaprost (DE-126/ONO-9054): Santen Inc./Ono Pharmaceutical


13.9. NCX 470: Nicox Ophthalmics


13.10. Bamosiran (SYL040012): Sylentis


13.11. ENV515 (Travoprost XR): Envisia Therapeutics


13.12. Nyxol (Phentolamine Mesylate): Ocuphire Pharma


13.13. POLAT-001: Peregrine Ophthalmic


13.14. Failed Therapies


13.15. Trabodenoson: Inotek Pharmaceuticals


13.16. OTX-TP (Travoprost): Ocular Therapeutix


14. Open-Angle Glaucoma 7MM Market Analysis


15. United States: Market Outlook


15.1. United States Market Size


16. EU-5 countries: Market Outlook


16.1. Germany Market Size


16.2. France Market Size


16.3. Italy Market Size


16.4. Spain Market Size


16.5. United Kingdom Market Size


17. Japan Market Outlook


18. Access and Reimbursement Overview of Open Angle Glaucoma


19. Market Drivers


20. Market Barriers


21. SWOT Analysis


22. Appendix


23. DelveInsight Capabilities


24. Disclaimer


25. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:


SOURCE DelveInsight




Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States